Development and Validation of a Serologic Test Panel for Detection of Powassan Virus Infection in U.S. Patients Residing in Regions Where Lyme Disease Is Endemic

Angela M. Thomm, Anna M. Schotthoefer, Alan P. Dupuis II, Laura D. Kramer, Holly M. Frost, Thomas R. Fritsche, Yvette A. Harrington, Konstance K. Knox, Sue C. Kehl

ABSTRACT  Powassan virus (POWV) is an emerging tick-borne arbovirus presenting a public health threat in North America. POWV lineage II, also known as deer tick virus, is the strain of the virus most frequently found in Ixodes scapularis ticks and is implicated in most cases of POWV encephalitis in the United States. Currently, no commercial tests are available to detect POWV exposure in tick-borne disease (TBD) patients. We describe here the development and analytical validation of a serologic test panel to detect POWV infections. The panel uses an indirect enzyme immunoassay (EIA) to screen. EIA-positive samples reflex to a laboratory-developed, POWV-specific immunofluorescence assay (IFA). The analytical sensitivity of the test panel was 89%, and the limit of detection was a plaque reduction neutralization test (PRNT) titer of 1:20. The analytical specificity was 100% for the IgM assay and 65% for the IgG assay when heterologous-flavivirus-positive samples were tested. On samples collected from regions where Lyme disease is endemic, seroprevalence for POWV in TBD samples was 9.4% (10 of 106) versus 2% when tested with non-TBD samples (2 of 100, P = 0.034). No evidence of POWV infection was seen in samples collected from a region where Lyme disease was not endemic (0 of 22). This test panel provides a sensitive and specific platform for detecting a serologic response to POWV early in the course of infection when neutralizing antibodies may not be detectable. Combined with clinical history, the panel is an effective tool for identifying acute POWV infection.

IMPORTANCE  Approximately 100 cases of POWV disease were reported in the United States over the past 10 years. Most cases have occurred in the Northeast (52) and Great Lakes (45) regions (https://www.cdc.gov/powassan/statistics.html). The prevalence of POWV in ticks and mammals is increasing, and POWV poses an increasing threat in a greater geographical range. In areas of the Northeast and Midwest where Lyme disease is endemic, POWV testing is recommended for patients with a recent tick bite, patients with Lyme disease who have been treated with antibiotics, or patients with a tick exposure who have tested negative for Lyme disease or other tick-borne illnesses and have persistent symptoms consistent with posttreatment Lyme disease. Testing could also benefit patients with tick exposure and unexplained neurologic symptoms and chronic fatigue syndrome (CFS) patients with known tick exposure. Until now, diagnostic testing for Powassan virus has not been commercially available and has been limited to patients presenting with severe, neurologic complications. The lack of routine testing for Powassan virus in patients with suspected tick-borne disease means that little information is available regarding the overall prevalence of the virus and the
full spectrum of clinical symptoms associated with infection. As *Ixodes scapularis* is the tick vector for Powassan virus and multiple other tick-borne pathogens, including the Lyme disease bacterium, *Borrelia burgdorferi*, the clinical presentations and long-term outcomes of Powassan virus infection and concurrent infection with other tick-borne disease pathogens remain unknown.

**KEYWORDS** Powassan virus, deer tick virus, enzyme immunoassay, flavivirus, immunofluorescence, serology, tick-borne disease, tick-borne encephalitis

Powassan virus (POWV) is the only North American member of the tick-borne encephalitis complex (TBE-C) of viruses, which are transmitted by the bite of an infected tick. Other members of the TBE-C include the following flaviviruses: tick-borne encephalitis virus (TBEV) in Eastern Europe and Western Asia, Omsk hemorrhagic fever virus in Siberia, Kyasanur Forest disease virus in India, Alkhurma virus in Saudi Arabia, and Louping ill virus in the United Kingdom. TBE-C viruses can cause a wide range of disease in humans, from mild febrile illness with biphasic fever to encephalitis or hemorrhagic fever (1). POWV is composed of two genetically and ecologically distinct lineages (2). Prototype POWV (lineage I) is transmitted primarily by *Ixodes cookei*, a tick with a narrow vertebrate host range that rarely feeds on humans. Powassan virus lineage II, also known as deer tick virus (DTV), is transmitted by *Ixodes scapularis*, a tick with a broad host range that also transmits the infectious agents that cause Lyme disease, anaplasmosis, ehrlichiosis, and babesiosis (3). Since the late 1990s, POWV infections have been reported in the Northeastern and Midwestern parts of the United States as well as in Canada, and incidence is increasing (4). Because the territory of *I. scapularis* is expanding and the prevalence of POWV in ticks and mammals is increasing, POWV poses an increasing threat (5, 6). In a recent survey, *I. scapularis* ticks collected from the northwest quadrant of Wisconsin from 2011 to 2012 demonstrated a POWV infection frequency of 4.67% (7). This is similar in frequency to a survey conducted in that same area in 1998 (8). Although POWV is rarely diagnosed as a cause of encephalitis, infections can be severe, and neurologic sequelae are common (9). Additionally, the potential for concurrent transmission with other tick-borne pathogens, particularly *Borrelia burgdorferi*, the causative agent of Lyme disease, has not been previously studied in North America.

Similarly to other arboviral infections, POWV diagnosis is complex, requiring review of clinical and travel history in addition to knowledge of and access to diagnostic testing (10). Serologic testing remains the primary method for diagnosis of POWV infection, with an emphasis on the detection of POWV-specific IgM antibodies in serum or plasma. Until recently, commercial laboratory testing has been unavailable for POWV in the United States. Prior to this, a positive POWV IgM enzyme immunoassay (EIA) result confirmed by plaque reduction neutralization test (PRNT), a 4-fold or greater increase in titers between acute- and convalescent-phase sera, or culture or direct identification of virus-specific nucleic acids at a state public health laboratory or the Centers for Disease Control and Prevention (CDC) (11) has been the mainstay of diagnostic testing.

We describe here a laboratory-developed, serologic test panel, commercially available at a reference laboratory, for the detection of IgG and IgM antibodies to POWV in serum and plasma samples. The first test in the panel is a highly sensitive, commercial TBE-C screen by EIA. Per the manufacturer, cross-reactivity with other flaviviruses is expected, particularly with West Nile virus (WNV) and dengue virus (DENV) antibody-positive samples. Samples that are screen positive are then confirmed for POWV by indirect immunofluorescence assay (IFA). Performance characteristics of the test panel were optimized, and validation studies were performed to assess the analytical sensitivity, reproducibility, and specificity/cross-reactivity of the serologic test panel for use in routine diagnostic testing.
RESULTS

Assay optimization and analytical sensitivity. No difference in sensitivity was observed between the viral strains tested or between lots of slides. A sample dilution of 1:20 for IgM and 1:40 for POWV IgG IFAs demonstrated the optimal balance between sensitivity and nonspecific background staining (Fig. 1). Tick-borne disease (TBD) samples with titers of 1:320 and 1:160 in the plaque reduction neutralization test (PRNT) were assayed at optimized screening dilutions to confirm. All but one of the POWV encephalitis samples obtained from the New York State Department of Health (NYSDOH) with PRNT90 titers of 1:20 were detected by the TBE-C EIA screen and confirmatory POWV IFA. A PRNT90 titer of 1:20 was determined to be the limit of detection (LOD) for the serologic test panel and was confirmed as such using known PRNT90-positive samples (Table 1). At these screening dilutions, the serologic panel showed an analytical sensitivity of 89% (Table 1). Reproducibility studies showed 100% accordance ($k = 1.0$).

Analytical specificity. Due to limited sample volume availability for the heterologous-flavivirus (HF) sample set, only yellow fever virus (YFV) vaccinee samples could be analyzed in replicate runs at two different dilutions to check IFA specificity. A sample known to be positive for YFV IgG antibodies (vaccinee 3) had a positive POWV IgG IFA result at a 1:20 dilution but was negative at a 1:40 dilution. A sample known to be positive for YFV IgM antibodies (vaccinee 1) had a positive POWV IgM IFA result at a 1:10 dilution but was negative at a 1:20 dilution (Fig. 2). Both of these samples were negative when tested at the optimized screening dilutions used for the panel. Only one recent YFV vaccine sample demonstrated cross-reactivity in the POWV IgG IFAs (Table 2) when assayed at optimal screening dilutions.

The HF samples demonstrated significant cross-reactivity in the TBE-C IgG EIA, but at a 1:40 dilution, the POWV IgG IFA specificity for non-TBE-C HF samples was 65% (Table 2). This is comparable to other commercial IFAs. Fewer HF samples demonstrated
cross-reactivity in the TBE-C IgM EIA than in the TBE-C IgG EIA, and no cross-reactivity was seen in the POWV IgM IFA with any of the HF samples run at screening dilutions (Table 3).

**Clinical testing.** Twenty-two (20%) of the TBD samples had TBE-C optical density (OD) ratios above baseline and were tested in the POWV confirmatory IFA. One-half of these samples \( n = 11 \), Table 4) were IFA positive for antibodies to POWV. Two of the three POWV IgG IFA-positive samples were PRNT \(_{90}\) positive (samples 13 and 19). The third sample (sample 12) was negative in the PRNT \(_{90}\) and West Nile virus (WNV) IgG positive, demonstrating evidence of cross-reactivity in the POWV IgG IFA. All eight samples that were positive only in the POWV IgM IFA were negative in the PRNT. POWV nucleic acid was detectable by reverse transcription-PCR (RT-PCR) in one sample (sample 16 in Table 4). POWV seroprevalence for the TBD sample set was determined to be 9.4% (10 of 106).

Of the 100 non-TBD samples from areas where Lyme disease is endemic, 23% \( n = 23 \) had TBE-C EIA OD ratios higher than baseline and were tested by POWV IFA. Six of the 23 EIA-positive samples were IFA positive for antibodies to POWV (Table 5), with

### TABLE 1

Summary of POWV serologic data for arbovirus encephalitis panel sample set

| Sample no. | TBE-C EIA IgM | POWV IFA IgM | TBE-C EIA IgG | POWV IFA IgG | POWV PRNT \(_{90}\) titer |
|------------|---------------|--------------|---------------|--------------|--------------------------|
| 1          | +             | ND           | +             | ≥1:40        | 1:5,120                  |
| 2          | +             | ND           | +             | ≥1:40        | 1:640                    |
| 3          | +             | ND           | +             | ≥1:40        | 1:2,560                  |
| 4          | ND            | ≥1:20        | +             | ≥1:40        | 1:320                    |
| 5          | +             | ≥1:20        | ND            | ≥1:40        | 1:5120                   |
| 6          | ND            | ≥1:20        | +             | ≥1:100       | 1:10,240                 |
| 7          | +             | ND           | ≥1:100        | 1:40,960     |
| 8          | ND            | ND           | ND            | 1:20         |
| 9          | +             | ≥1:20        | ND            | ≥1:40        | 1:20                     |

\(^{a}\)Overall POWV results were as follows: \( n = 9 \) (8 positive, 1 negative) and overall test panel sensitivity of 89%.

\(^{b}\)ND, not detected at screening dilutions of 1:101 for TBE-C EIA, 1:20 for POWV IgM IFA, and 1:40 for POWV IgG IFA.

FIG 2

Yellow fever virus (YFV) vaccine recipient plasma samples in Powassan virus (POWV) indirect immunofluorescence assay (IFA) to determine optimal screening dilutions to eliminate cross-reactivity. (Top) YFV IgG-positive sample 7 years postvaccine assayed at 1:20 (left) and 1:40 (right) dilutions in IgG IFA. (Bottom) YFV IgM-positive sample 4 weeks postvaccine assayed at 1:10 (left) and 1:20 (right) dilutions in POWV IgM IFA.
four samples being IgG IFA positive and two samples IFA positive for IgG and IgM. Three of the four IgG IFA-positive samples were positive for WNV IgG, again demonstrating cross-reactivity of the IgG with WNV. The fourth sample was negative by PRNT90. POWV seroprevalence for the non-TBD sample set was determined to be 2% (2 of 100). Patients with suspected TBD, who were tested for Lyme disease, are significantly ($P < 0.034$) more likely to have evidence of POWV infection than asymptomatic patients from an area where Lyme disease is endemic but who did not have a history of recent tick exposure.

Six of the 22 control samples from an area in which Lyme disease was not endemic had TBE-C EIA OD ratios above the cutoff in the IgM assay, but none were positive in the POWV IFAs (0 of 22). None of these samples were above the cutoff in the TBE-C IgG EIA.

## DISCUSSION

Studies confirm that serologic cross-reactions among the flaviviruses are significant and more frequently observed with IgG antibody detection assays. Both commercial EIAs and IgG IFA demonstrate poor specificity overall, with IFA being slightly better than EIA. The overall specificity of flavivirus IgG EIAs is reported between 16 and 38% and improves slightly to 29 to 84% for IgG IFAs (12). The addition of the POWV IgG IFA to the TBE-C EIA screen eliminated 35% of the cross-reactivity seen with the EIA alone. The immunological maturation of the IgG antibody response tends to foster the formation of antibodies directed to epitopes with greater likelihood for cross-reactivity (13). While the specificity of flavivirus PRNTs detecting neutralizing IgG antibodies is high, this often comes at the cost of assay sensitivity. A PRNT$_{50}$ tends to be more sensitive in detecting early antibody responses, given the less stringent endpoint of

### TABLE 2

| Cluster and sample identifier (source) | Phylogenetic clade | Antigenic complex | Result for assay: |
|---------------------------------------|-------------------|------------------|------------------|
| TBEV IgG (Euroimmun)                  | IV                | TBE              | +               |
| TBEV IgG/M* patient serum             | IV                | TBE              | +               |
| DENV IgG (Euroimmun)                  | IX                | DEN              | +               |
| DENV IgG (SeraCare)                   | IX                | DEN              | +               |
| DENV IgM (SeraCare)                   | IX                | DEN              | +               |
| WNV IgG 1 (SeraCare)                  | XIV               | JE               | +               |
| WNV IgG 2 (SeraCare)                  | XIV               | JE               | +               |
| WNV IgG (Euroimmun)                   | XIV               | JE               | +               |
| WNV IgM 1 (SeraCare)                  | XIV               | JE               | +               |
| WNV IgM 2 (SeraCare)                  | XIV               | JE               | +               |
| JEV IgG (Euroimmun)                   | XIV               | JE               | +               |
| YFV IgG (Euroimmun)                   | VII               | Not classified   | +               |
| YFV vaccinee serum 1                  | VII               | Not classified   | ND              |
| YFV vaccinee serum 2                  | VII               | Not classified   | +               |
| YFV vaccinee serum 3                  | VII               | Not classified   | +               |
| YFV vaccinee serum 4                  | VII               | Not classified   | ND              |
| YFV vaccinee serum 5                  | VII               | Not classified   | ND              |
| YFV vaccinee serum 6                  | VII               | Not classified   | ND              |
| YFV vaccinee serum 7                  | VII               | Not classified   | ND              |

|  |  |  | ND |

*Phylogenetic and antigenic classification based on the work of Kuno et al. (24).

**Abbreviations:** DENV, dengue virus; WNV, West Nile virus; TBEV, tick-borne encephalitis virus; JEV, Japanese encephalitis virus; YFV, yellow fever virus; ND, not detected at screening dilutions of 1:101 for TBE-C EIA and 1:40 for POWV IgG IFA.

*IgA results for POWV-negative samples (n = 19) were as follows: 2 from the tick cluster, both positive; 17 from the mosquito cluster, 6 positive and 11 negative; overall IgG IFA positive specificity, 65%. The analytical specificity calculation includes the mosquito-borne virus cluster only (n = 17).*

---

January/February 2018 Volume 3 Issue 1 e00467-17

msphere.asm.org
50% reduction in plaques, versus the highly specific 90% plaque reduction described here (14). Also, low correlation between PRNT and IFA titer is not surprising since the IFA detects antibodies to a variety of structural and nonstructural viral proteins, whereas the PRNT primarily detects neutralizing antibodies directed to the envelope (E) protein of the virus (13). When tested against non-tick-borne flavivirus samples, the POWV IgG IFA described here demonstrated an analytical specificity of 65%, comparable to that of other commercial flavivirus IgG IFAs (15).

The overall cross-reactivity associated with detection of flavivirus IgM antibodies is significantly lower than that seen with IgG antibodies, and IgM IFA specificity was 20 to

### TABLE 3

Summary of data for HF sample set included in POWV IgM IFA analytical specificity studies

| Cluster and sample identifier (source) | Phylogenetic clade | Antigenic complex | TBE-C EIA IgM | POWV IFA IgM |
|---------------------------------------|--------------------|-------------------|---------------|--------------|
| Tick-borne virus cluster              |                    |                   |               |              |
| TBEV IgM (Euroimmun)                  | IV                 | TBE               | +             | ND           |
| TBEV IgG/M+ patient serum             | IV                 | TBE               | +             | ND           |
| Mosquito-borne virus cluster          |                    |                   |               |              |
| DENV IgM (Euroimmun)                  | IX                 | DEN               | ND            | ND           |
| DENV IgM (SeraCare)                   | IX                 | DEN               | ND            | ND           |
| DENV IgG (SeraCare)                   | IX                 | DEN               | ND            | ND           |
| WNV IgM 1 (SeraCare)                  | XIV                | JE                | ND            | ND           |
| WNV IgM 2 (SeraCare)                  | XIV                | JE                | ND            | ND           |
| WNV IgM (Euroimmun)                   | XIV                | JE                | ND            | ND           |
| WNV IgG 1 (SeraCare)                  | XIV                | JE                | ND            | ND           |
| WNV IgG 2 (SeraCare)                  | XIV                | JE                | ND            | ND           |
| JEV IgG (Euroimmun)                   | XIV                | JEV               | +             | ND           |
| YFV vaccine serum 1                   | VII                | Not classified    | +             | ND           |
| YFV vaccine serum 2                   | VII                | Not classified    | +             | ND           |
| YFV vaccine serum 3                   | VII                | Not classified    | ND            | ND           |
| YFV vaccine serum 4                   | VII                | Not classified    | ND            | ND           |
| YFV vaccine serum 5                   | VII                | Not classified    | ND            | ND           |
| YFV vaccine serum 6                   | VII                | Not classified    | ND            | ND           |
| YFV vaccine serum 7                   | VII                | Not classified    | +             | ND           |

Phylogenetic and antigenic classification based on the work of Kuno et al. (24).
Eighty-six percent positive at protein level for members of tick-borne virus cluster.
Abbreviations: DENV, dengue virus; WNV, West Nile virus; TBEV, tick-borne encephalitis virus; JEV, Japanese encephalitis virus; YFV, yellow fever virus; ND, not detected at screening dilutions of 1:101 for TBE-C EIA and 1:20 for POWV IgM IFA.

IFA results for POWV-negative samples were as follows: \( n = 18 \) (2 from tick cluster and 16 from mosquito cluster), 0 positive samples, and POWV IgM IFA positive specificity of 100% (analytical specificity calculation includes mosquito-borne virus cluster only \( n = 16 \)).

### TABLE 4

Summary of POWV serologic data for TBD sample set

| Sample no. | TBE-C EIA IgM | POWV IFA IgM | POWV IFA IgG | POWV PRNT titer |
|------------|---------------|--------------|--------------|-----------------|
| 10         | +             | ≥1:20        | ND*          | ND              |
| 11         | +             | ≥1:20        | ND           | ND              |
| 12         | ND            | ND           | +            | 1:160           |
| 13         | ND            | ND           | +            | 1:40            |
| 14         | +             | ≥1:20        | ND           | ND              |
| 15         | +             | ≥1:20        | ND           | ND              |
| 16         | +             | ≥1:20        | ND           | ND              |
| 17         | +             | ≥1:20        | ND           | ND              |
| 18         | +             | ≥1:20        | ND           | ND              |
| 19         | +             | ≥1:20        | +            | 1:320           |
| 20         | +             | ≥1:20        | ND           | ND              |

*ND, not detected at screening dilutions of 1:101 for TBE-C EIA, 1:20 for POWV IgM IFA, and 1:40 for POWV IgG IFA and 1:10 for POWV PRNT.
*Sample tested positive for IgG antibodies to WNV.
*POWV RNA detected in RT-PCR test.
30% higher than IgM EIA when patients with suspected flavivirus infections were screened for several different viruses (12). The addition of the POWV IgM IFA to the TBE-C EIA screen eliminated 55% of the cross-reactivity seen with the IgM EIA alone. Many commercially available flavivirus IgM-specific serologic tests report sensitivity lower than that seen with IgG assays, due primarily to the fact that PRNT is considered the gold standard for the differential serodiagnosis. Published reports confirm that, in patients with primary flavivirus infection, the IgM response likely consists of antibodies with minimal to no virus-neutralizing capacity (16, 17). In a study assessing the performance of a commercially available WNV IgM EIA, 14 of 44 CDC IgM protocol-negative samples were found positive. The apparent lack of IgM specificity observed with that assay may be attributed to the use of PRNT to confirm IgM positives as part of the CDC protocol (18). In studies where convalescent-phase samples can be collected from patients 2 to 4 weeks after infection, the use of PRNT may be helpful to confirm the accuracy of acute-phase detection of IgM. In the studies presented here, we were limited by design to samples collected only at the time of clinical presentation, and therefore, follow-up convalescent-phase samples were not available. The lack of a reliable and accurate predicate assay for use as a gold standard when developing flavivirus IgM assays requires further study.

According to the World Health Organization (WHO), a single IgM-positive result for arboviral diagnosis is considered a presumptive positive and should be confirmed by RT-PCR, virus isolation, and/or PRNT to discriminate potentially cross-reactive antibodies (19). In the current study, one POWV IgM IFA-positive sample was confirmed positive by POWV RT-PCR with the remaining IgM IFA-positive samples lacking detectable viral genome. Studies performed with WNV IgM-positive patients show that viremia can be detected for an average of 7 days and that IgM antibody becomes detectable a median of 4 days after the midpoint of the interval for RNA detection, for an overlap of only 1 to 2 days (20). Therefore, RT-PCR cannot function as a sensitive confirmatory assay for IgM-positive samples across all time points.

### Table 5

| Sample no. | TBE-C EIA IgM | POWV IFA IgM | WNV EIA IgM | TBE-C EIA IgG | POWV IFA IgG | WNV EIA IgG |
|------------|---------------|--------------|-------------|---------------|--------------|-------------|
| 21         | ND            | ND           | ND          | ND            | ND           | ND          |
| 22         | +             | ND           | ND          | ND            | ≥1:40        | +           |
| 23         | ND            | ND           | ND          | ND            | ND           | ND          |
| 24         | ND            | ND           | ND          | ND            | ND           | ND          |
| 25         | ND            | ND           | ND          | ND            | ≥1:40        | +           |
| 26         | +             | ND           | ND          | ND            | ND           | ND          |
| 27         | ND            | ND           | ND          | ND            | ≥1:40        | +           |
| 28         | +             | ND           | ND          | ND            | ND           | ND          |
| 29         | ND            | ND           | ND          | ND            | ND           | ND          |
| 30         | +             | ND           | ND          | ND            | +            | ND          |
| 31         | +             | ND           | ND          | ND            | ND           | ND          |
| 32         | +             | ND           | ND          | ND            | ND           | ND          |
| 33         | +             | ND           | ND          | ND            | ND           | ND          |
| 34         | +             | ND           | ND          | ND            | ND           | ND          |
| 35         | +             | ND           | ND          | ND            | ND           | ND          |
| 36         | ND            | ND           | ND          | ND            | ND           | ND          |
| 37         | +             | ND           | ND          | ND            | ≥1:40        | ND          |
| 38         | +             | ND           | ND          | ND            | ND           | ND          |
| 39         | +             | ND           | ND          | ND            | ≥1:40        | ND          |
| 40         | +             | ND           | ND          | ND            | ND           | ND          |
| 41         | ND            | ND           | ND          | ND            | ND           | ND          |
| 42         | ND            | ND           | ND          | ND            | ND           | ND          |
| 43         | +             | ND           | ND          | ND            | ND           | ND          |

*aND, not detected at screening dilutions of 1:101 for TBE-C and WNV EIA, 1:20 for POWV IgM IFA, and 1:40 for POWV IgG IFA.
*bSample tested positive for IgG antibodies to WNV with an OD ratio of >3.0.
*cSample was tested in POWV PRNT and not detected.
The current state of diagnostics for POWV infection includes initial serological testing performed using IgM capture enzyme-linked immunosorbent assay (ELISA) and IgG ELISA with confirmatory testing utilizing PRNT, a 4-fold or greater increase in antibody titer between acute- and convalescent-phase sera, virus isolation, or detection of virus-specific RNA. Only a few state health labs and the CDC offer this testing, and the labor-intensive nature of the confirmatory tests often delays the reporting of final results beyond the period of clinical utility. In addition, testing is usually limited to patients presenting with neurologic complications; therefore, little is known regarding the overall prevalence of and clinical symptoms associated with POWV infection. Limited data regarding cocirculation of Lyme disease and POWV seroprevalence in the Midwest have been published (21). The test panel described here allows for the simple and efficient detection of acute POWV infection. However, due to the cross-reactivity seen for all flavivirus IgG assays, it is imperative that exposure to other flaviviruses and travel and vaccination history be considered when interpreting IgG test results. This panel is a diagnostic tool that can play an important role in further defining the full spectrum of POWV disease.

Materials and Methods

Samples for assay development. (i) Serum samples submitted for arbovirus encephalitis panel testing. Optimization and analytical sensitivity studies were performed using POWV antibody-positive serum samples confirmed by PRNT using a 90% reduction cutoff (PRNT_{90}) (22). These samples had been submitted to the New York State Department of Health (NYSDOH) Arbovirus Laboratory (n = 9) for testing against an arbovirus encephalitis panel. 

(ii) Heterologous-flavivirus sample set. The heterologous-flavivirus (HF) sample set consists of 11 human serum/plasma samples known to be IgM antibody positive and 12 samples known to be IgG antibody positive to heterologous flaviviruses, including dengue virus (DENV) and West Nile virus (WNV) (SeraCare’s bank of disease state biological materials; Milford, MA) and Japanese encephalitis virus (JEV), yellow fever virus (YFV), and TBEV (Euroimmun US). Another seven samples collected from YFV strain 17D vaccine recipients at various time points postvaccination were included in the HF sample set.

Clinical samples to assess seroprevalence. (i) TBD sample set. The tick-borne disease sample set consists of 106 serum/plasma samples submitted for Lyme disease testing from patients residing in Wisconsin, an area in which Lyme disease is endemic (23). Patients were considered to have suspected TBD if a Lyme disease serology test was ordered by their provider. Eleven serum samples were submitted to Coppe Laboratories for routine Lyme disease testing, deidentified, and included in this study. Ninety-five serum/plasma samples provided by the Marshfield Clinic Research Foundation (MCRF) were residual diagnostic samples which had been submitted to Marshfield Clinic for Lyme disease testing. The 95 samples from MCRF were part of an institutional review board (IRB)-approved research protocol. 

(ii) Non-TBD sample set. The non-TBD sample set collected from areas in which Lyme disease is endemic consists of 100 serum/plasma samples collected from patients without symptoms of TBD and without history or evidence of recent tick exposure. Fifty heparinized whole-blood samples from healthy, asymptomatic adults were purchased from Analytical Biological Services (ABS), Inc. (Wilmington, DE), and processed in-house to plasma. These samples were collected locally for biospecimen banking, in the northeast region of the United States, where Lyme disease is endemic (23). Fifty plasma samples were collected by the Marshfield Clinic from residual diagnostic samples submitted for routine cholesterol or complete metabolic panel screening. These samples were collected from subjects living in the same geographic area as the TBD subjects and were part of the same IRB-approved protocol.

(iii) Control sample set. The control sample set from a region where Lyme disease is not endemic consists of 22 samples collected from patients residing near Reno, NV. These samples, submitted to Coppe Laboratories for human herpesvirus testing, were deidentified and included in the study.

Test methods. (i) TBE-C EIA method. Samples were screened for the presence of IgG and IgM antibodies to TBE-C using anti-TBEV ELISA IgG (Euroimmun catalog no. EI-2661-9601G) and anti-TBEV ELISA IgM (Euroimmun catalog no. EI-2661-9601M) per the manufacturer’s recommended assay protocol. These assays employ inactivated TBEV antigens of strain K23. Optical density (OD) ratio values were calculated for each sample in reference to a calibrator provided with the test kit. Any samples with an OD ratio that exceeded the baseline value were reflexed to confirmatory POWV IFA. 

(ii) IFA method. An in-house strain of Powassan virus lineage II, sequence-confirmed deer tick virus (DTV) isolated from an I. scapularis tick pool, along with viral reference strains Powassan LB and DTV CT390 (World Reference Center for Emerging Viruses and Arboviruses, Galveston, TX), was cultured in Vero cells and used to prepare IFA substrate slides. Three different culture techniques were tested to determine the best slide manufacturing conditions. Vero cells infected with POWV were grown on eight-well chamber slides using optimized culture conditions. Slides were fixed in 2% neutral buffered formalin (NBF) followed by 100% cold methanol and stored at −20°C until use. Prior to testing, substrate slides were warmed for 30 min in a humidity chamber at room temperature and blocked with 2% normal goat serum (Vector Laboratories, Burlingame, CA) for an additional 30 min. Patient serum and/or plasma samples, positive and negative controls, were diluted 1:40 in 2% normal goat serum for IgG analysis and 1:20 in Eurosorb (Euroimmun US) anti-human IgG antibody buffer for IgM analysis, added to slide wells,
and incubated for 60 min at 37°C. After 1 h of incubation, the slides were washed 3 times with phosphate-buffered saline (PBS), and 50 μl of DyLight 488 anti-human IgM (μ-specific) secondary antibody (Vector Laboratories) diluted 1:200 was added to each well. The slides were incubated for 30 min and washed three times in PBS. The slides were counterstained with Evans blue, rinsed with distilled water, mounted using Vectashield mounting medium (Vector Laboratories), and examined using an epifluorescence microscope. Positive- and negative-control samples were included in all IFA runs.

(iii) Optimization of IFA. Titrations of fluorescein-conjugated anti-human secondary antibodies were performed to determine the optimal concentration for the assay. Sample titration experiments were performed to determine optimal screening dilutions for IFAs that yield acceptable sensitivity while minimizing cross-reaction with the heterologous flavivirus (HF) sample set. Low-PRNT90-titer samples were analyzed in duplicate assays at optimal screening dilutions to determine the lower limit of detection (LOD) for the IFA. Reproducibility was assessed by testing 26 samples (17 positive samples and 9 negative samples) in duplicate assays.

(iv) WNV method. Samples were tested for the presence of IgG and IgM antibodies to WNV by qualitative ELISA (Euroimmun US), and results were analyzed per the manufacturer’s recommended protocol.

(v) Clinical testing. All 106 TBD samples were tested for TBE-C by EIA. Any samples with TBE-C OD ratios above baseline were tested with the optimized POWV IFA and WNV EIA. POWV IFA-positive samples were submitted to NYSDOH for PRNT. A PRNT90 rather than a PRNT50 was used to ensure specificity, though the expected sensitivity is lower (22).

All 100 non-TBD samples were tested for TBE-C and WNV by EIA. Samples with higher-than-baseline TBE-C OD ratios were tested with the optimized POWV IFA. The two Marshfield Clinic samples that were POWV IFA positive were also tested by PRNT90.

The 22 control samples were tested for TBE-C by EIA, and any samples with above-baseline OD ratios reflexed to confirmatory IFA.

(vi) Statistical analysis. Analytical sensitivity was calculated as (true positives)/(true positives + false negatives) × 100. Analytical specificity was determined using the arbovirus encephalitis panel. Analytical specificity was calculated as (true negatives)/(true negatives + false positives) × 100. The limit of detection was calculated as the lowest PRNT90 titer detected in the POWV IgM assay. Analytical specificity was determined using the HF sample set. Seroprevalence was calculated for each of the TBD, non-TBD, and control sample sets. Due to the inability of PRNT90 to be used for confirmation of POWV IgM and the lack of cross-reactivity seen with the HF samples, samples that were POWV IgM IFA positive or POWV IgG positive and confirmed by PRNT90 were presumed to be true positives. For samples that were negative for POWV IgM by IFA, POWV IgG was considered a false positive if WNV IgG was positive or PRNT90 was negative.

ACKNOWLEDGMENTS

We thank the World Reference Center for Emerging Viruses and Arboviruses and the University of Texas Medical Branch for providing virus stock for POWV strain LB and DTV strain CT390. We thank Euroimmun US for providing EIA kits for validation studies as well as control samples for IFA cross-reactivity testing. K.K.K. and A.M.S. conceived and designed the study; A.M.T. designed the experiments; A.M.T. and Y.A.H. performed the experiments; A.M.T., K.K.K., and S.C.K. analyzed the data; A.M.S., T.R.F., H.M.F., A.P.D., and L.D.K. provided patient samples and clinical data; A.P.D. and L.D.K. provided PRNT90 data; A.M.T., K.K.K., and S.C.K. wrote the paper.

REFERENCES

1. Lehrer AT, Holbrook MR. 2011. Tick-borne encephalitis vaccines. J Biol- error Biodef 2011:3. https://doi.org/10.4172/2157-2526.51-003.

2. Ebel GD, Spielman A, Telford SR, III. 2001. Phylogeny of North American Powassan virus. J Gen Virol 82:1657–1665. https://doi.org/10.1099/0022-1317-82-8-1657.

3. Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, Krause PJ, Bakken JS, Nadelman RB. 2006. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the IDSA. CID 43:1089–1134. https://doi.org/10.1086/508667.

4. Ebel GD. 2010. Update on Powassan virus: emergence of a North American tick-borne flavivirus. Annu Rev Entomol 55:95–110. https://doi.org/ 10.1146/annurev-ento-112408-120846.

5. Eisen RJ, Eisen L, Beard CB. 2016. County-scale distribution of Ixodes scapularis and Ixodes pacificus (Acarina: Ixodidae) in the continental United States. J Med Entomol 53:349–386. https://doi.org/10.1093/jme/ tnv237.

6. Nofchissey RA, Deadriff ER, Blevins TM, Anishchenko M, Bosco-Lauth A, Berle E, Lubelczyk C, Mutebi JP, Brault AC, Ebel GD, Magnarelli LA. 2013. Seroprevalence of Powassan virus in New England deer, 1979–2010. Am J Trop Med Hyg 88:1159–1162. https://doi.org/10.4269/ajtmh.12-0586.

7. Knox KK, Thomm AM, Harrington YA, Ketter E, Pattucci JM, Carrigan DR. 2017. Powassan/deer tick virus and Borrelia burgdorferi infection in Wisconsin tick populations. Vector Borne Zoonotic Dis 17:463–466. https://doi.org/10.1089/vbz.2016.2082.

8. Ebel GD, Foppan I, Spielman A, Telford SR. 1999. A focus of deer tick virus transmission in the northcentral United States. Emerg Infect Dis 5:570–574. https://doi.org/10.3201/eid0504.990423.

9. Gritsun TS, Nuttall PA, Gould EA. 2003. Tick-borne flaviviruses. Adv Virus Res 61:317–371. https://doi.org/10.1016/S0065-3527(03)61008-0.

10. SunSung S, Wurcel AG, Whittier S, Kulas K, Kramer LD, Flam R, Roberts JK, Tsiouris S. 2013. Powassan meningoencephalitis, New York, New York, USA. Emerg Infect Dis 19:9. https://doi.org/10.3201/eid1909.121846.

11. Centers for Disease Control and Prevention. 9 February 2015. Powassan virus. Clinical and lab evaluations. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/powassan/clinicallabeval.html.
12. Koraka P, Zeller H, Niedrig M, Osterhaus AD, Groen J. 2002. Reactivity of serum samples from patients with a flavivirus infection measured by immunofluorescence assay and ELISA. Microbes Infect 4:1209–1215. https://doi.org/10.1016/S1286-4579(02)01647-7.

13. Niedrig M, Sonnenberg K, Steinhagen K, Paweska JT. 2007. Comparison of ELISA and immunoassays for measurement of IgG and IgM antibody to West Nile virus in human sera against virus neutralization. J Virol Methods 139:103–105. https://doi.org/10.1016/j.jviromet.2006.09.009.

14. Park SW, Perera RAPM, Choe PG, Lau EHY, Choi SJ, Chun JY, Oh HS, Song KH, Bang JH, Kim ES, Kim HB, Park WB, Kim NJ, Poon LLM, Peiris M, Oh MD. 2015. Comparison of serological assays in human Middle East respiratory syndrome (MERS)-coronavirus infection. Euro Surveill 20:41. https://doi.org/10.2807/1560-7917.ES.2015.20.41.30042.

15. Domingo C, Alves MU, de Ory F, Teichmann A, Schmitz H, Müller R, Niedrig M. 2015. International external quality control assessment for the serological diagnosis of dengue infections. BMC Infect Dis 15:167. https://doi.org/10.1186/s12879-015-0877-0.

16. Roehrig JT, Hombach J, Barrett ADT. 2008. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol 21:123–132. https://doi.org/10.1089/vim.2008.0007.

17. Ledermann JP, Lorono-Pino MA, Ellis C, Saxton-Shaw KD, Blitvich BJ, Beatty BJ, Bowen RA, Powers AM. 2011. Evaluation of widely used diagnostic tests to detect West Nile virus infections in horses previously infected with St. Louis encephalitis virus or dengue virus type 2. Clin Vaccine Immunol 18:580–587. https://doi.org/10.1128/CVI.00201-10.

18. Hogrefe WR, Moore R, Lape-Nixon ML, Wagner M, Prince HE. 2004. Performance of immunoglobulin G (IgG) and IgM enzyme-linked immunoassortent assays using a West Nile virus recombinant antigen (preM/E) for detection of West Nile virus- and other flavivirus-specific antibodies. J Clin Microbiol 42:4641–4648. https://doi.org/10.1128/JCM.42.10.4641-4648.2004.

19. Niedrig M, Kürsteiner O, Herzog C, Sonnenberg K. 2008. Evaluation of an indirect immunofluorescence assay for detection of immunoglobulin M (IgM) and IgG antibodies against yellow fever virus. Clin Vaccine Immunol 15:177–181. https://doi.org/10.1128/CVI.00078-07.

20. Busch MP, Kleinman SH, Tobler LH, Kamel HT, Norris PJ, Walsh I, Matud JL, Prince HE, Lanciotti RS, Wright DJ, Linnen JM, Cagnioli S. 2008. Virus and antibody dynamics in acute West Nile virus infection. J Infect Dis 198:984–993. https://doi.org/10.1086/591467.

21. Frost HM, Schotthoefer AM, Thomm AM, Dupuis AP, II, Kehl SC, Kramer LD, Fritsche TR, Harrington YA, Knox KK. 2017. Serologic evidence of Powassan virus infection in patients with suspected Lyme disease. Emerg Infect Dis 23:1384–1388. https://doi.org/10.3201/eid2308.161971.

22. Dupuis AP, Peters RJ, Prusinski MA, Falco RC, Ostfeld RS, Kramer LD. 2013. Isolation of deer tick virus (Powassan virus, lineage II) from *Ixodes scapularis* and detection of antibody in vertebrate hosts sampled in the Hudson Valley, New York State. Parasit Vectors 6:185. https://doi.org/10.1186/1756-3305-6-185.

23. Centers for Disease Control and Prevention. 13 November 2017. Lyme disease. Data and statistics. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/lyme/stats/index.html.

24. Kuno G, Chang GJ, Tsuchiya KR, Karabatsos N, Cropp CB. 1998. Phylogeny of the genus Flavivirus. J Virol 72:73–83.